![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png?w=350&fit=crop&auto=format)
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, MBBS, PhD, MRCP, FRCPath.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
Advertisement
Articles by Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the EHA 2025 Congress.
Advertisement
Latest Updated Articles
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png?w=300&fit=crop&auto=format)
JNJ-5322 Shows Efficacy in Later-Line Multiple MyelomaPublished: June 27th 2025 | Updated:
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple MyelomaPublished: June 26th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
3
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
4
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
5
